GLP\u20111<\/a> receptor activation.<\/p>\n
\n\t\t\t
\n\t\t\t
<\/p>\n
More insulin is released only when glucose is high, which lowers blood sugar with a lower risk of hypoglycaemia compared with drugs that stimulate insulin regardless of glucose level.<\/p>\n
\n\t\t\t
\n\t\t\t
<\/p>\n
Canadian clinical guidance for GLP\u20111 receptor agonists (including semaglutide) notes they \u201cincrease glucose\u2011dependent insulin secretion\u201d in type 2 diabetes<\/p>\n
\n\t\t\t
\n\t\t
\n\t\t
\n\t\t\t
<\/p>\n
Pancreatic alpha cells (glucagon)<\/p>\n
\n\t\t\t
\n\t\t\t
<\/p>\n
Semaglutide suppresses inappropriate glucagon secretion from pancreatic alpha cells when glucose is high.<\/p>\n
\n\t\t\t
\n\t\t\t
<\/p>\n
Lower glucagon reduces hepatic (liver) glucose output, contributing to improved fasting and post\u2011meal blood glucose control.<\/p>\n
\n\t\t\t
\n\t\t\t
<\/p>\n
Canadian endocrinology and diabetes overviews of GLP\u20111 RAs state they \u201creduce inappropriately elevated glucagon\u201d as a key mechanism for lowering blood glucose in type 2 diabetes<\/p>\n
\n\t\t\t
\n\t\t
\n\t\t
\n\t\t\t
<\/p>\n
Stomach \/ gut (gastric emptying)<\/p>\n
\n\t\t\t
\n\t\t\t
<\/p>\n
Semaglutide slows gastric emptying through GLP\u20111 receptor action in the gastrointestinal tract.<\/p>\n
\n\t\t\t
\n\t\t\t
<\/p>\n
Food moves more slowly from the stomach to the intestine, which blunts post\u2011meal (post\u2011prandial) glucose spikes and improves satiety.<\/p>\n
\n\t\t\t
\n\t\t\t
<\/p>\n
Health Canada labelling for GLP\u20111 RAs used in Canada (including semaglutide) notes delayed gastric emptying as a mechanism affecting post\u2011prandial glycaemia<\/p>\n
\n\t\t\t
\n\t\t
\n\t\t
\n\t\t\t
<\/p>\n
Brain (appetite and satiety)<\/p>\n
\n\t\t\t
\n\t\t\t
<\/p>\n
In the brain, semaglutide activates GLP\u20111 receptors in appetite\u2011regulation centres, increasing satiety and reducing appetite.<\/p>\n
\n\t\t\t
\n\t\t\t
<\/p>\n
Patients tend to eat less and feel full sooner, which reduces caloric intake and supports clinically meaningful weight loss, particularly relevant where obesity and type 2 diabetes coexist.<\/p>\n
\n\t\t\t
\n\t\t\t
<\/p>\n
Canadian obesity and diabetes guidance describing GLP\u20111 RAs (including semaglutide) highlight central appetite effects leading to \u201creduced energy intake and weight loss\u201d<\/p>\n
\n\t\t\t
\n\t\t
\n\t\t
\n\t\t\t
<\/p>\n
Overall glucose control<\/p>\n
\n\t\t\t
\n\t\t\t
<\/p>\n
By combining increased insulin (when glucose is high), reduced glucagon, slower gastric emptying and reduced intake, semaglutide lowers fasting and post\u2011meal blood glucose and improves HbA1c.<\/p>\n
\n\t\t\t
\n\t\t\t
<\/p>\n
Better glycaemic control reduces risk of diabetes complications (e.g., cardiovascular, kidney and eye disease), which can lower long\u2011term health and disability costs for employers.<\/p>\n
\n\t\t\t
\n\t\t\t
<\/p>\n
Health Canada\u2011authorised Product Monographs for semaglutide list improved HbA1c and fasting\/post\u2011prandial glucose as primary efficacy outcomes in type 2 diabetes<\/p>\n
\n\t\t\t
\n\t\t
\n\t\t
\n\t\t\t
<\/p>\n
Body weight \/ cardiometabolic risk<\/p>\n
\n\t\t\t
\n\t\t\t
<\/p>\n
Through reduced appetite and energy intake, semaglutide leads to clinically significant weight loss, particularly at obesity\u2011indicated doses.<\/p>\n
\n\t\t\t
\n\t\t\t
<\/p>\n
Weight reduction can improve blood pressure, lipids and glycaemic control, potentially lowering cardiometabolic risk and related claims over time.<\/p>\n
\n\t\t\t
\n\t\t\t
<\/p>\n
Health Canada approvals of higher\u2011dose semaglutide for weight management, together with Canadian obesity guidelines, describe sustained weight loss via GLP\u20111\u2013mediated appetite reduction and energy\u2011intake lowering\u00a0<\/p>\n
\n\t\t\t
\n\t\t
<\/p>\n","protected":false},"excerpt":{"rendered":"
Where it acts \/ mechanism
What semaglutide does (mechanism of action)
…\n","protected":false},"author":2,"featured_media":26149,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[17,12699,1855,12114],"class_list":["post-26148","post","type-post","status-publish","format-standard","has-post-thumbnail","category-canada","tag-canada","tag-glp-1","tag-health-canada","tag-semaglutide"],"_links":{"self":[{"href":"https:\/\/www.europesays.com\/canada\/wp-json\/wp\/v2\/posts\/26148","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/canada\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/canada\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/canada\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/canada\/wp-json\/wp\/v2\/comments?post=26148"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/canada\/wp-json\/wp\/v2\/posts\/26148\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/canada\/wp-json\/wp\/v2\/media\/26149"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/canada\/wp-json\/wp\/v2\/media?parent=26148"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/canada\/wp-json\/wp\/v2\/categories?post=26148"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/canada\/wp-json\/wp\/v2\/tags?post=26148"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}